Mizuho raised the firm’s price target on Harmony Biosciences (HRMY) to $48 from $44 and keeps an Outperform rating on the shares post the Q1 report. The firm left the quarter “pleased,” given a Wakix revenue beat and no negative pipeline surprises, with lead asset Wakix “steadily rumbling toward” becoming a $1B product. Miuzho is most focused on Harmony’s pipeline, which features six programs that are expected to be in Phase 3 by the end of 2025.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HRMY:
- Harmony Biosciences Holdings: Strong Market Position and Growth Potential Justify Buy Rating
- Sell Rating for Harmony Biosciences Holdings Due to Patent Litigation Risks and Speculative Pipeline
- Harmony Biosciences Reports Strong Q1 2025 Results
- Harmony Biosciences Reports Strong Earnings and Growth
- Positive Outlook for Harmony Biosciences: Strong EPS Performance and Strategic Growth Initiatives Support Buy Rating